including biological fluid-based biomarkers, electrophysiological biomarkers and neuroimaging biomarkers. Within the first category, phosphorylated neurofilament heavy and neurofilament light seem to be the most promising ones. Based on published data, phosphorylated neurofilament heavy and neurofilament light levels in cerebrospinal fluid (and potentially in plasma) may have a role as prognostic biomarkers. Thus, they could be used in clinical trials to facilitate the stratification of study participants into treatment arms on the basis of anticipated rates of disease progression (Boylan et al., 2013) . Regarding electrophysiological biomarkers, the motor unit number index (MUNIX) is gaining relevance (Nandedkar et al., 2004) . MUNIX is a relatively easy technique which would theoretically allow to capture disease progression very early in the disease course, at a time when common neurophysiological parameters CMAP remained relatively stable. Unfortunately, this potential benefit is offset by the fact that repeatability of MUNIX is usually lowest early in the disease and improves only as the disease progresses into advanced stages (Felice, 1997; Bromberg, 2007) . Among neuroimaging biomarkers, structural imaging analysis such as voxel based morphometry consistently show atrophy in the precentral gyrus in ALS patients compared to healthy volunteers (Menke et al., 2014) . MRI tractography has also been evaluated revealing changes at corticospinal tract as disease progresses (Keil et al., 2012) . However, further studies are needed to validate these results. Finally, fluorodeoxyglucose-positron emission tomogra-phy studies have revealed hypometabolism in the precentral girus and frontal regions in ALS subjects (Van Laere et al., 2014) and it may be an independent predictor of shorter survival (Van Laere et al., 2014) .
It can be anticipated that a combination of validated humoral, electrophysiologic and imaging biomarkers will probably provide a dynamic understanding of the disease and its progression as well as the eventual response to a particular therapy more firmly that any single biomarker (Benatar et al., 2016) .
Second, from an epidemiological point of view, there is a rapid-growing list of environmental factors that have been associated to ALS . In addition to the classical ones, such as exposure to heavy metals, toxicants as paraformaldehyde or cyanotoxins, new categories of environmental factors and lifestyle characteristic are being including in that list. In recent years, some microorganisms, particularly retroviruses and gut microbiota dysregulation, have been associated with the genesis of the disease (Castanedo-Vazquez et al., 2018) . Furthermore, lifestyle and other demographic parameters such as physical activity, nutrition, body mass index, cardiovascular risk factors, autoimmune diseases and cancer are being associated to the disease. Differently from most other neurodegenerative diseases, increased body mass index and metabolic syndrome have been related to an increased risk of ALS (Gallo et al., 2013) . The association with autoimmunity and cancer is also intriguing: patients with previous autoimmune diseases and oncological history have been reported to have increased and decreased risk of ALS, respectively (Turner et al., 2013; Gibson et al., 2016) . New research about the associations between ALS and comorbid conditions will doubtlessly provide new perspectives of the disease and will help us to better understand it .
Third, from a molecular perspective, ALS should also be considered as a very complex condition. Familial forms of the disease, which represent about 10 percent cases, appear as "pure" forms, directly derived from mutations not only in the genes encoding neuron-damaging proteins, but also in genes that are involved in a variety of cellular functions, including RNA processing, autophagy, vesicular transport and energy metabolism (Zufiría et al., 2016) . The mechanisms leading to disease in sporadic cases may be much more complex and at least as heterogeneous as those in familial forms. In any case, once the pathogenic process has been initiated, a plethora of metabolic and other cellular alterations precipitate a vicious cycle in ALS and other neurodegenerative diseases favouring disease progression (Zufiría et al., 2016) . In other words, abnormalities in neuronal functions are often related to the combination of alterations at several levels, including alterations of gene processing (impaired DNA/RNA regulation, epigenetic aberrations), increased oxidative stress, mitochondrial dysfunction, proteostasic abnormalities, energetic imbalance, axonal transport deficits and glial cell dysfunction (Riancho et al., 2016b) .
Based on this perception of the disease, several disease models, including cellular models and more complex animal models have been created by using molecular biology tools. Unfortunately, after accumulating a huge amount of data, experimental outcomes have not been translated into effective preventive or therapeutic strategies. This lack of success might respond to several reasons. Perhaps, we should consider that extrapolations and inferences may have been made in a too simplistic manner, as animal models of the disease commonly reproduce just a particular feature, rather than the whole process. In addition, we may have not paid enough attention to other factors of the internal and external environmental that influence the disease course.
If we do agree with the idea that in ALS there are several pathways involved, with multiple inter-actions building a complex pathogenic network, we should consider a modern perspective about causation (Rothman and Greenland, 2005) . In this model, a causative factor could be unique (such as mutation in a causative gene) but more frequently could also be composed of several causal components that could be grouped in different manners constituting different sufficient causes (which may or may not share some of the component causes).
When a component cause is present in all the sufficient causes it must be considered a necessary cause (Rothman and Greenland, 2005) . It seems clear that according to this model, research focused on just one or two component causes will continue yielding very partial results with serious difficulties in reformulating a theory that generates valid predictive models.
These focused approaches derive, at least partially, from the structure of research funding programs. According to this new concept, research funding strategies should firmly support integrated programs of investigation considering ALS as a global neurodegenerative process rather than the result of a variety of isolated pathogenic events. These integrated projects should doubtlessly involve multi-disciplinary groups that focus together on the same problem by using different models and analytical tools, but always subordinated to a common hypothesis (Figure 2) .
In conclusion, we think that a multidisciplinary holistic approach to ALS-related questions is needed to better understand the pathogenesis of the disease and advance into more effective therapies. An open, honest and cooperative relationship between academia and industry, as well as between industry and health regulatory authorities will foster translational research programs leasing to effective therapies. Integrated projects must include multi-disciplinary groups that focus together on the same problem by using different models and analytical tools, being always subordinated to a common hypothesis. IPSCs: Induced pluripotent stem cells.
